Saquinavir: Difference between revisions
David Canner (talk | contribs) New page: <applet load="" size="480" color="" frame="true" spin="on" Scene ="Indinavir/Indinavir/1" align="right" caption="Saquinavir, better known as Invirase, (1hsg)"/> ===Better Known as: ... |
David Canner (talk | contribs) No edit summary |
||
| Line 5: | Line 5: | ||
* Drug Class: [[HIV Protease]] Inhibitor | * Drug Class: [[HIV Protease]] Inhibitor | ||
* Date of FDA Approval (Patent Expiration): 1995 (2010) <br /> | * Date of FDA Approval (Patent Expiration): 1995 (2010) <br /> | ||
* | * 2004 Sales: $100 Million | ||
* Importance: It was the first [[HIV Protease]] inhibitor to be approved by the FDA. Due to the rapidity with which HIV developed resistance to Saquinavir, Roche halted sales of Saquinavir monotreatments in favor of combination treatments with [[Ritonavir]]. | * Importance: It was the first [[HIV Protease]] inhibitor to be approved by the FDA. Due to the rapidity with which HIV developed resistance to Saquinavir, Roche halted sales of Saquinavir monotreatments in favor of combination treatments with [[Ritonavir]]. | ||
* The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | * The following is a list of Pharmacokinetic Parameters. See: [[Pharmaceutical Drugs]] for more information | ||